Santen Pharmaceutical-Un ADRSNPHY
13F holders, Q4 2025 (December 31)2holders
0new positions
0sold out
$10.30avg. 13F price*
At the end of Q4 2025, 2 institutions reported holding Santen Pharmaceutical-Un ADR (SNPHY) in their 13F filings, unchanged from Q3 2025. 0 opened new positions and 0 sold out. The largest holders were Rhumbline Advisers ($12K) and Copeland Capital Management, LLC ($3K).
- Company
- Santen Pharmaceutical-Un ADR
- CUSIP
- 80287P100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 2 holders
| Rhumbline Advisers | 0.00% | No change | 1,197 | $12K |
| Copeland Capital Management, LLC | 0.00% | No change | 286 | $3K |
"% of holder's portfolio" is SNPHY's weight in each manager's 13F, not the share of Santen Pharmaceutical-Un ADR the manager owns.